Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of ZSP1603 capsules in patients with idiopathic pulmonary fibrosis
CTR20211366Phase 2Active
- Sponsor
- Zhongsheng Pharma
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZSP1603 in idiopathic pulmonary fibrosis (IPF), sponsored by Zhongsheng Pharma. Started Oct 2021; status: active.
02
Drugs
ZSP1603
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20211366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211366.